HomeQuestion

Should atezolimab and chemotherapy be considered for stage III dMMR colon cancer with BRAF mutation?

Join the Discussion

Discuss the cases and questions guidelines don't cover.

Related Questions

What adjuvant treatment approach would you recommend for a patient with early-stage MSI-high gastric cancer who received neoadjuvant ipilimumab (×2) and nivolumab (×6) per the NEONIPIGA regimen, followed by R0 resection with no pathologic response?

How, if at all, are you modifying your practice and clinical workflow for patients receiving checkpoint inhibitors with data showing improved outcomes for patients receiving infusions earlier in the day?

Is there a role for stents for patients with a new diagnosis of metastatic upper rectal cancer with a near-obstructing primary?

Which patients with resectable/borderline resectable pancreas adenocarcinoma are you offering perioperative PAXG Abraxane/cisplatin/capecitabine/gemcitabine?

Is there a role for adjuvant chemotherapy in a locally recurrent stage I rectal adenocarcinoma, initially treated surgically, and received concurrent chemoradiation with capecitabine at recurrence at anastomosis?

Evidence Meets Expertise

For Physicians

Mednet AI
Community

Company

About
Careers
Publications
Blog

Support

FAQs
Code of Conduct
AI Community Guidelines
Contact Us
Programs

Legal

Privacy Policy
Terms of Service

© 2026 Mednet Inc. All rights reserved.